SXTC
China SXT Pharmaceuticals Inc
NASDAQ: SXTC · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$0.05
-8.85% today
Updated 2026-07-29
Market cap
$93.63M
P/E ratio
—
P/S ratio
82.28x
EPS (TTM)
$-8.67
Dividend yield
—
52W range
$1 – $312
Volume
17.1M
WallStSmart proprietary scores
23
out of 100
Grade: F
Strong Sell
Investment rating
4.7
Growth
C8.0
Quality
A2.5
Profitability
F5.0
Valuation
C+2/9
Piotroski F-Score
Weak
2.6
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
—
—
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.04x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-2.26M
- Revenue declining -43.90% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.97M | $1.93M | $1.74M | $1.07M | $1.14M |
| Net income | $-5.93M | $-3.10M | $-3.30M | $-6.21M | $163718.00 |
| EPS | — | — | — | — | $-8.67 |
| Free cash flow | $-151441.00 | $-1.94M | $-2.35M | $-4.02M | $-2.26M |
| Profit margin | -301.00% | -160.67% | -189.77% | -578.49% | — |
Peer comparison
Smart narrative
China SXT Pharmaceuticals Inc trades at $0.05. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 2.55, it sits in the grey zone. TTM revenue stands at $1.14M.
Frequently asked questions
What is China SXT Pharmaceuticals Inc's stock price?
China SXT Pharmaceuticals Inc (SXTC) trades at $0.05, on a P/S of 82.3x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is China SXT Pharmaceuticals Inc overvalued?
China SXT Pharmaceuticals Inc carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is China SXT Pharmaceuticals Inc's revenue?
China SXT Pharmaceuticals Inc's trailing twelve-month revenue is $1.14M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
China SXT Pharmaceuticals Inc's Altman Z-Score is 2.55, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryChina
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio82.28x
ROE-50.30%
Beta1.82
50D MA$2.02
200D MA$79.11
Shares out0.04B
Float0.03B
Short ratio—
Avg volume17.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—